Society for Endocrinology - a world-leading authority on hormones

EMA recommends approval of new somatostatin analogue pasireotide (Signifor) for Cushing’s disease (NeLM News Service, 20 January 2012)

23 Jan 2012


The European Medicines Agency has made a positive recommendation to the European Commission for EU approval for Novartis' Signifor (pasireotide) in the treatment of Cushing's disease.

Full article